SmithKline Beecham Relafen Patent Infringement Trial Set For October
Patent infringement litigation between SmithKline Beecham and three generic companies seeking approval for versions of Relafen (nabumetone) is scheduled to begin in October.
Patent infringement litigation between SmithKline Beecham and three generic companies seeking approval for versions of Relafen (nabumetone) is scheduled to begin in October.